These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 37158938)
1. First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors. Zhao Y; Ma Y; Zang A; Cheng Y; Zhang Y; Wang X; Chen Z; Qu S; He J; Chen C; Jin C; Zhu D; Li Q; Liu X; Su W; Ba Y; Hao Y; Chen J; Zhang G; Qu S; Li Y; Feng W; Yang M; Liu B; Ouyang W; Liang J; Yu Z; Kang X; Xue S; Yang G; Yan W; Yang Y; Liu Z; Peng Y; Fanslow B; Huang X; Zhang L; Zhao H J Hematol Oncol; 2023 May; 16(1):50. PubMed ID: 37158938 [TBL] [Abstract][Full Text] [Related]
2. Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors. Ma Y; Xue J; Zhao Y; Zhang Y; Huang Y; Yang Y; Fang W; Guo Y; Li Q; Ge X; Sun J; Zhang B; Zhang Y; Xiao J; Zhang L; Zhao H J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37263673 [TBL] [Abstract][Full Text] [Related]
3. QL1706 (anti-PD-1 IgG4/CTLA-4 antibody) plus chemotherapy with or without bevacizumab in advanced non-small cell lung cancer: a multi-cohort, phase II study. Huang Y; Yang Y; Zhao Y; Zhao H; Zhou N; Zhang Y; Chen L; Zhou T; Chen G; Wu T; Lu L; Xue S; Kang X; Zhang L; Fang W Signal Transduct Target Ther; 2024 Jan; 9(1):23. PubMed ID: 38282003 [TBL] [Abstract][Full Text] [Related]
4. Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial. Kim TW; Bedard PL; LoRusso P; Gordon MS; Bendell J; Oh DY; Ahn MJ; Garralda E; D'Angelo SP; Desai J; Hodi FS; Wainberg Z; Delord JP; Cassier PA; Cervantes A; Gil-Martin M; Wu B; Patil NS; Jin Y; Hoang T; Mendus D; Wen X; Meng R; Cho BC JAMA Oncol; 2023 Nov; 9(11):1574-1582. PubMed ID: 37768658 [TBL] [Abstract][Full Text] [Related]
5. Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial. Tang B; Chen Y; Jiang Y; Fang M; Gao Q; Ren X; Yao L; Huang G; Chen J; Zhang X; Li R; Zhao S; Gao M; Luo R; Qi M; Li F; Zheng F; Lee M; Tao X; Duan R; Guo J; Chi Z; Cui C J Immunother Cancer; 2024 Oct; 12(10):. PubMed ID: 39366752 [TBL] [Abstract][Full Text] [Related]
6. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors. Frentzas S; Austria Mislang AR; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38642937 [TBL] [Abstract][Full Text] [Related]
7. A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced or metastatic solid tumors. Huang Z; Xu Y; Hong W; Gong L; Chen K; Qin J; Xie F; Wang F; Tian X; Meng X; Feng W; Li L; Zhang B; Kang X; Fan Y Front Immunol; 2023; 14():1258573. PubMed ID: 37936687 [TBL] [Abstract][Full Text] [Related]
8. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer Niu J; Maurice-Dror C; Lee DH; Kim DW; Nagrial A; Voskoboynik M; Chung HC; Mileham K; Vaishampayan U; Rasco D; Golan T; Bauer TM; Jimeno A; Chung V; Chartash E; Lala M; Chen Q; Healy JA; Ahn MJ Ann Oncol; 2022 Feb; 33(2):169-180. PubMed ID: 34800678 [TBL] [Abstract][Full Text] [Related]
9. A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study). Zhao Y; Ma Y; Fan Y; Zhou J; Yang N; Yu Q; Zhuang W; Song W; Wang ZM; Li B; Xia Y; Zhao H; Zhang L Lung Cancer; 2023 Oct; 184():107355. PubMed ID: 37677918 [TBL] [Abstract][Full Text] [Related]
10. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719 [TBL] [Abstract][Full Text] [Related]
11. Dual CTLA-4 and PD-1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first-in-human, dose-escalation, and dose-expansion study. Bishnoi S; Kotasek D; Aghmesheh M; Yau T; Cosman R; Prawira A; Moore M; Chan SL; Mant A; Eek R; Zielinski R; Su R; Pan Z; Ma Y; Li F; Li P; Tse AN Cancer; 2024 Jun; 130(11):1991-2002. PubMed ID: 38404184 [TBL] [Abstract][Full Text] [Related]
12. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962 [TBL] [Abstract][Full Text] [Related]
13. First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors. Hamid O; Chiappori AA; Thompson JA; Doi T; Hu-Lieskovan S; Eskens FALM; Ros W; Diab A; Spano JP; Rizvi NA; Wasser JS; Angevin E; Ott PA; Forgie A; Yang W; Guo C; Chou J; El-Khoueiry AB J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36302562 [TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Perets R; Bar J; Rasco DW; Ahn MJ; Yoh K; Kim DW; Nagrial A; Satouchi M; Lee DH; Spigel DR; Kotasek D; Gutierrez M; Niu J; Siddiqi S; Li X; Cyrus J; Chackerian A; Chain A; Altura RA; Cho BC Ann Oncol; 2021 Mar; 32(3):395-403. PubMed ID: 33276076 [TBL] [Abstract][Full Text] [Related]
15. A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors. Falchook GS; Peeters M; Rottey S; Dirix LY; Obermannova R; Cohen JE; Perets R; Frommer RS; Bauer TM; Wang JS; Carvajal RD; Sabari J; Chapman S; Zhang W; Calderon B; Peterson DA Invest New Drugs; 2021 Oct; 39(5):1284-1297. PubMed ID: 33852104 [TBL] [Abstract][Full Text] [Related]
16. Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study. Shen L; Guo J; Zhang Q; Pan H; Yuan Y; Bai Y; Liu T; Zhou Q; Zhao J; Shu Y; Huang X; Wang S; Wang J; Zhou A; Ye D; Sun T; Gao Y; Yang S; Wang Z; Li J; Wu YL J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561638 [TBL] [Abstract][Full Text] [Related]
17. Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors. Kollmannsberger C; Hurwitz H; Bazhenova L; Cho BC; Hong D; Park K; Reckamp KL; Sharma S; Der-Torossian H; Christensen JG; Faltaos D; Potvin D; Tassell V; Chao R; Shapiro GI Target Oncol; 2023 Jan; 18(1):105-118. PubMed ID: 36459255 [TBL] [Abstract][Full Text] [Related]
18. Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer. Cho BC; Yoh K; Perets R; Nagrial A; Spigel DR; Gutierrez M; Kim DW; Kotasek D; Rasco D; Niu J; Satouchi M; Ahn MJ; Lee DH; Maurice-Dror C; Siddiqi S; Ren Y; Altura RA; Bar J Lung Cancer; 2021 Sep; 159():162-170. PubMed ID: 34371366 [TBL] [Abstract][Full Text] [Related]
19. A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations. Heymach J; Opdam F; Barve M; Gibson N; Sadrolhefazi B; Serra J; Yamamoto N Clin Lung Cancer; 2023 Mar; 24(2):e65-e68. PubMed ID: 36528522 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, safety, and efficacy of an alternative dosing regimen of sasanlimab in participants with advanced NSCLC and other malignancies. Penkov K; Bondarenko I; Saenko DV; Kulyaba Y; Guo J; Gong Y; Yamamoto N; Hotko YS; Boyko V; Fadeeva NV; Ursol GM; Ahn HK; Kislov NV; Shen CI; Davis C; Kowalski K; Michelon E; Pavlov D; Hirohashi T; Cho BC Ther Adv Med Oncol; 2024; 16():17588359241274592. PubMed ID: 39281971 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]